

26 May 2026

CHANGE TO CEO REMUNERATION

PERTH, Australia and SAN FRANCISCO, California – 26 May 2026

PYC Therapeutics Limited (ASX:PYC) (PYC or the Company) is a precision medicine Company dedicated to changing the lives of patients with genetic diseases who have no treatment options available.

The Company today announces that it has revised the remuneration paid to its Chief Executive Officer, Dr. Rohan Hockings, following an independent review of the Company's remuneration practices. The revision is designed to ensure the Company is aligned to market practices and recognises the role of the CEO in building long-term value for shareholders.

A copy of the key terms of Dr. Hockings revised remuneration is set out in Annexure A to this announcement.

About PYC Therapeutics

PYC Therapeutics (ASX: PYC) is a clinical-stage biotechnology company creating a new generation of RNA therapies to change the lives of patients with genetic diseases. The Company utilises its proprietary drug delivery platform to enhance the potency of precision medicines within the rapidly growing and commercially proven RNA therapeutic class. PYC's drug development programs target monogenic diseases – the indications with the highest likelihood of success in clinical development¹.

For more information, visit pyctx.com, or follow us on [LinkedIn](#).

¹ Advancing Human Genetics Research and Drug Discovery through Exome Sequencing of the UK Biobank
<https://doi.org/10.1101/2020.11.02.2022232>

Annexure A – Summary of revised CEO remuneration – Dr. Rohan Hockings

Name	Rohan Hockings
Role	Chief Executive Officer
Effective Date	1 May 2026
Fixed Annual Remuneration	\$900,000
Short Term Incentive (STI)	STI at Target of 55% of FAR with a Stretch/Maximum of 110% of FAR. Performance metrics will be set by the Board and evaluation of performance will be conducted by the Board.
Long Term Incentive (LTI)	LTI at Target of 85% of FAR with a Stretch/Maximum of 170% of FAR. Performance metrics will be set by the Board and evaluation of performance will be conducted by the Board.

Forward looking statements

Any forward-looking statements in this ASX announcement have been prepared on the basis of a number of assumptions which may prove incorrect and the current intentions, plans, expectations, and beliefs about future events are subject to risks, uncertainties and other factors, many of which are outside the Company's control. Important factors that could cause actual results to differ materially from assumptions or expectations expressed or implied in this ASX announcement include known and unknown risks. Because actual results could differ materially to assumptions made and the Company's current intentions, plans, expectations, and beliefs about the future, you are urged to view all forward-looking statements contained in this ASX announcement with caution. The Company undertakes no obligation to publicly update any forward-looking statement whether as a result of new information, future events or otherwise.

This ASX announcement should not be relied on as a recommendation or forecast by the Company. Nothing in this ASX announcement should be construed as either an offer to sell or a solicitation of an offer to buy or sell shares in any jurisdiction.

This ASX announcement was approved and authorised for release by the Board of PYC Therapeutics Limited

CONTACT US

Investor relations and media contact

investor@pyctx.com

